Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 117 of 117 entries
View as:

A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

Phase: N/A Priority: Normal
NCT ID: NCT03739840 Org: User:
Start: 03/06/19 End: 09/28/20 Due: 09/28/21

A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis

Phase: N/A Priority: Normal
NCT ID: NCT03355573 Org: User:
Start: 11/28/17 End: 10/19/22 Due: 10/19/23

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT06055985 Org: User:
Start: 11/17/23 End: 04/11/25 Due: 04/11/26

A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants

Phase: N/A Priority: Normal
NCT ID: NCT04255862 Org: User:
Start: 02/12/20 End: 04/26/21 Due: 04/26/22

A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment

Phase: N/A Priority: Normal
NCT ID: NCT04627285 Org: User:
Start: 12/28/20 End: 02/12/25 Due: 02/12/26

A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT04740814 Org: User:
Start: 02/11/21 End: 06/27/22 Due: 06/27/23

A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants

Phase: N/A Priority: Normal
NCT ID: NCT06315335 Org: User:
Start: 07/01/24 End: 01/01/25 Due: 01/01/26

A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

Phase: N/A Priority: Normal
NCT ID: NCT05292131 Org: User:
Start: 03/17/22 End: 01/09/23 Due: 01/09/24

A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants

Phase: N/A Priority: Normal
NCT ID: NCT05626439 Org: User:
Start: 12/28/22 End: 02/24/23 Due: 02/24/24

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT03347110 Org: User:
Start: 11/22/17 End: 10/29/20 Due: 10/29/21

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants

Phase: N/A Priority: Normal
NCT ID: NCT04444466 Org: User:
Start: 06/30/20 End: 08/02/21 Due: 08/02/22

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT05020249 Org: User:
Start: 09/27/21 End: 09/06/22 Due: 09/06/23

A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants

Phase: N/A Priority: Normal
NCT ID: NCT05315947 Org: User:
Start: 04/04/22 End: 05/13/22 Due: 05/13/23

An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT05514873 Org: User:
Start: 10/31/22 End: 10/23/24 Due: 10/23/25

An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT05543252 Org: User:
Start: 08/29/22 End: 03/25/25 Due: 03/25/26

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis

Phase: N/A Priority: Normal
NCT ID: NCT03928704 Org: User:
Start: 04/25/19 End: 04/17/23 Due: 04/17/24

A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU

Phase: N/A Priority: Normal
NCT ID: NCT03020992 Org: User:
Start: 12/21/16 End: 01/23/20 Due: 01/23/21